newsfilter
← Latest News
GlobeNewswire·

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA